Ami Batchelder

965 total citations
13 papers, 692 citations indexed

About

Ami Batchelder is a scholar working on Hematology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ami Batchelder has authored 13 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 5 papers in Pathology and Forensic Medicine and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ami Batchelder's work include Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Multiple Sclerosis Research Studies (3 papers). Ami Batchelder is often cited by papers focused on Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (4 papers) and Multiple Sclerosis Research Studies (3 papers). Ami Batchelder collaborates with scholars based in United States and South Africa. Ami Batchelder's co-authors include George B. McDonald, H. Gary Schoch, M Bouvier, Claudio Anasetti, John T. Slattery, Song Ren, Ted Gooley, Thomas F. Kalhorn, Jeannine S. McCune and H. Joachim Deeg and has published in prestigious journals such as Blood, Kidney International and Clinical Pharmacology & Therapeutics.

In The Last Decade

Ami Batchelder

13 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ami Batchelder United States 11 418 196 130 113 110 13 692
M Bouvier United States 11 427 1.0× 126 0.6× 175 1.3× 157 1.4× 51 0.5× 29 688
C D Hillyer United States 8 333 0.8× 89 0.5× 115 0.9× 22 0.2× 48 0.4× 10 478
F. Léger France 10 152 0.4× 65 0.3× 143 1.1× 30 0.3× 125 1.1× 11 476
Shari Lennon United States 9 327 0.8× 101 0.5× 69 0.5× 18 0.2× 49 0.4× 11 471
Wanda Górnik Poland 12 61 0.1× 92 0.5× 184 1.4× 33 0.3× 21 0.2× 25 508
G. Ehninger Germany 15 463 1.1× 110 0.6× 170 1.3× 53 0.5× 24 0.2× 56 859
A. de la Vega Spain 17 132 0.3× 45 0.2× 229 1.8× 18 0.2× 41 0.4× 38 1.0k
Neil Lyman United States 10 76 0.2× 47 0.2× 40 0.3× 69 0.6× 60 0.5× 11 385
John Rogosheske United States 17 358 0.9× 108 0.6× 214 1.6× 12 0.1× 198 1.8× 34 693
Enzo Andorno Italy 19 40 0.1× 228 1.2× 91 0.7× 66 0.6× 108 1.0× 85 1.2k

Countries citing papers authored by Ami Batchelder

Since Specialization
Citations

This map shows the geographic impact of Ami Batchelder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ami Batchelder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ami Batchelder more than expected).

Fields of papers citing papers by Ami Batchelder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ami Batchelder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ami Batchelder. The network helps show where Ami Batchelder may publish in the future.

Co-authorship network of co-authors of Ami Batchelder

This figure shows the co-authorship network connecting the top 25 collaborators of Ami Batchelder. A scholar is included among the top collaborators of Ami Batchelder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ami Batchelder. Ami Batchelder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Rezvani, Andrew R., Jeannine S. McCune, Barry E. Storer, et al.. (2013). Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. Biology of Blood and Marrow Transplantation. 19(7). 1033–1039. 61 indexed citations
3.
McCune, Jeannine S., Ami Batchelder, Robert P. Witherspoon, et al.. (2009). Personalized Dosing of Cyclophosphamide in the Total Body Irradiation–Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy. Clinical Pharmacology & Therapeutics. 85(6). 615–622. 58 indexed citations
4.
5.
Upton, Arlo, Jeannine S. McCune, Katharine A. Kirby, et al.. (2007). Fluconazole Coadministration Concurrent with Cyclophosphamide Conditioning May Reduce Regimen-Related Toxicity Postmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 13(7). 760–764. 17 indexed citations
6.
Woodahl, Erica L., Sangeeta Hingorani, Katherine A. Guthrie, et al.. (2007). Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. The Pharmacogenomics Journal. 8(4). 248–255. 14 indexed citations
7.
McCune, Jeannine S., Ami Batchelder, H. Joachim Deeg, et al.. (2007). Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality. Biology of Blood and Marrow Transplantation. 13(7). 853–862. 73 indexed citations
8.
Malone, Frances R., Wendy M. Leisenring, Barry E. Storer, et al.. (2007). Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplantation. 40(8). 765–772. 28 indexed citations
9.
McCune, Jeannine S., Ami Batchelder, Stewart T. Cole, et al.. (2005). Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clinical Pharmacology & Therapeutics. 78(3). 298–308. 22 indexed citations
10.
Hingorani, Sangeeta, et al.. (2004). Acute renal failure after myeloablative hematopoietic cell transplant: Incidence and risk factors. Kidney International. 67(1). 272–277. 95 indexed citations
11.
Qiu, Ruolun, Yao Assita, P. Vicini, et al.. (2004). Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. Clinical Pharmacology & Therapeutics. 76(3). 270–280. 21 indexed citations
12.
McDonald, George B., John T. Slattery, M Bouvier, et al.. (2003). Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 101(5). 2043–2048. 288 indexed citations
13.
Gorski, Jack, Stephen Apone, Kitt Shaffer, et al.. (2000). Hypercalcemia during the osteogenic phase after rat marrow ablation coincides with increased bone resorption assessed by the NTx marker. Bone. 27(1). 103–110. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Bouvier Breakdown of academic impact, for papers by C D Hillyer Breakdown of academic impact, for papers by F. Léger Breakdown of academic impact, for papers by Shari Lennon Breakdown of academic impact, for papers by Wanda Górnik Breakdown of academic impact, for papers by G. Ehninger Breakdown of academic impact, for papers by A. de la Vega Breakdown of academic impact, for papers by Neil Lyman Breakdown of academic impact, for papers by John Rogosheske Breakdown of academic impact, for papers by Enzo Andorno
Rankless by CCL
2026